{"id":"liraglutide-injection","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nausea"},{"rate":"5-15","effect":"Vomiting"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"10-20","effect":"Constipation"},{"rate":"5-10","effect":"Headache"},{"rate":"variable","effect":"Hypoglycemia (when combined with insulin or sulfonylureas)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural incretin hormone GLP-1. It binds to GLP-1 receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion, inhibits glucagon release when blood glucose is elevated, and delays gastric emptying to reduce postprandial glucose spikes. These combined effects lower blood glucose levels and reduce appetite, leading to weight loss.","oneSentence":"Liraglutide activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby reducing blood glucose and promoting weight loss.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:38.770Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Chronic weight management in obese or overweight patients"}]},"trialDetails":[{"nctId":"NCT07107334","phase":"PHASE2","title":"A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia","status":"RECRUITING","sponsor":"University of Florida","startDate":"2026-03","conditions":"Endometrioid Endometrial Adenocarcinoma","enrollment":20},{"nctId":"NCT05681299","phase":"PHASE4","title":"Effects of GH and Lirglutide on AgRP","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-05-01","conditions":"Healthy, Growth Hormone Deficiency","enrollment":40},{"nctId":"NCT07374445","phase":"PHASE4","title":"Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-09-01","conditions":"Obesity, Weight Loss, Bariatric Surgery","enrollment":100},{"nctId":"NCT05579249","phase":"PHASE4","title":"A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-19","conditions":"Obesity","enrollment":500},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT07244003","phase":"PHASE4","title":"Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-03-29","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":430},{"nctId":"NCT07225829","phase":"PHASE2","title":"A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis","status":"RECRUITING","sponsor":"4Moving Biotech","startDate":"2025-06-17","conditions":"Knee Osteoarthritis, Synovitis of Knee","enrollment":129},{"nctId":"NCT06976619","phase":"PHASE2","title":"The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-10-03","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":60},{"nctId":"NCT06171152","phase":"EARLY_PHASE1","title":"Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-01-26","conditions":"Multiple Sclerosis, Long COVID, Long Covid19","enrollment":30},{"nctId":"NCT06439056","phase":"PHASE1","title":"Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D","status":"COMPLETED","sponsor":"Nanexa AB","startDate":"2024-05-27","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT06374875","phase":"PHASE4","title":"Fibrosis Lessens After Metabolic Surgery","status":"RECRUITING","sponsor":"Ali Aminian","startDate":"2024-07-11","conditions":"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH)","enrollment":120},{"nctId":"NCT05221229","phase":"","title":"Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Birmingham","startDate":"2022-04-17","conditions":"Atrial Fibrillation, Recurrence, Overweight and Obesity","enrollment":29},{"nctId":"NCT02516657","phase":"PHASE3","title":"Liraglutide in Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2012-05","conditions":"Type 1 Diabetes","enrollment":5},{"nctId":"NCT06925334","phase":"PHASE4","title":"A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2024-05-20","conditions":"Type 2 Diabetic Patients","enrollment":170},{"nctId":"NCT03158805","phase":"PHASE2","title":"Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)","status":"COMPLETED","sponsor":"Lindner Center of HOPE","startDate":"2017-04-26","conditions":"Bipolar Disorder, Obesity","enrollment":60},{"nctId":"NCT04881110","phase":"PHASE4","title":"Liraglutide and Peripheral Artery Disease","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2021-02-01","conditions":"Type 2 Diabetes, Peripheral Arterial Disease","enrollment":60},{"nctId":"NCT05794581","phase":"PHASE1","title":"A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes","status":"COMPLETED","sponsor":"Carmot Therapeutics, Inc.","startDate":"2023-03-21","conditions":"Type 1 Diabetes","enrollment":32},{"nctId":"NCT06726577","phase":"PHASE1, PHASE2","title":"TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis","status":"RECRUITING","sponsor":"Talengen Institute of Life Sciences, Shenzhen, P.R. China.","startDate":"2024-12-10","conditions":"Amyotrophic Lateral Sclerosis","enrollment":60},{"nctId":"NCT06361238","phase":"PHASE3","title":"Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-11-19","conditions":"Delirium, Postoperative","enrollment":260},{"nctId":"NCT04883346","phase":"PHASE2","title":"Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2021-06-21","conditions":"Obesity, Status Post Sleeve Gastrectomy","enrollment":34},{"nctId":"NCT04199728","phase":"PHASE1, PHASE2","title":"Use of a GLP-1R Agonist to Treat Opioid Use Disorder","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2021-10-18","conditions":"Opiate Substitution Treatment, Opioid-Related Disorders","enrollment":27},{"nctId":"NCT04683237","phase":"PHASE2, PHASE3","title":"Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia","status":"WITHDRAWN","sponsor":"Xiaojun Chen","startDate":"2021-03-20","conditions":"Atypical Endometrial Hyperplasia, Obese, Fertility Issues","enrollment":""},{"nctId":"NCT06559722","phase":"PHASE3","title":"A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2024-08","conditions":"Type 2 Diabetes","enrollment":510},{"nctId":"NCT03036800","phase":"PHASE4","title":"Saxenda in Obesity Services (STRIVE Study)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2017-11-28","conditions":"Obesity, Weight Loss, Diabetes Mellitus","enrollment":392},{"nctId":"NCT02403284","phase":"PHASE4","title":"The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans","status":"COMPLETED","sponsor":"Phoenix VA Health Care System","startDate":"2013-03","conditions":"Insulin Resistance","enrollment":97},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT03856047","phase":"PHASE2","title":"Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-03-01","conditions":"Overweight, Obesity","enrollment":706},{"nctId":"NCT06449703","phase":"PHASE1","title":"A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects","status":"RECRUITING","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2024-05-06","conditions":"Healthy","enrollment":44},{"nctId":"NCT06438146","phase":"PHASE4","title":"LIROH - Liraglutide for Obesity in HIV","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-05-02","conditions":"Obesity, HIV Infections","enrollment":40},{"nctId":"NCT06408532","phase":"PHASE4","title":"The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-04-30","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT05390307","phase":"NA","title":"Obesity Treatment to Improve Diabetes","status":"COMPLETED","sponsor":"Dasman Diabetes Institute","startDate":"2023-04-01","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT01722240","phase":"PHASE3","title":"Liraglutide in Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2012-11-01","conditions":"Type 1 Diabetes","enrollment":69},{"nctId":"NCT06217848","phase":"EARLY_PHASE1","title":"The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2022-11-28","conditions":"Panhypopituitarism, Craniopharyngioma, Hypothalamic Obesity","enrollment":50},{"nctId":"NCT06201819","phase":"PHASE4","title":"Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery","status":"COMPLETED","sponsor":"Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca","startDate":"2022-12-18","conditions":"Weight Loss, Bariatric Surgery Candidate, Obesity, Morbid","enrollment":37},{"nctId":"NCT01722266","phase":"PHASE3","title":"Liraglutide in the Treatment of Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2012-11-01","conditions":"Type 1 Diabetes","enrollment":72},{"nctId":"NCT01508897","phase":"PHASE1","title":"Comparison of Two Liraglutide Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-05-28","conditions":"Diabetes, Healthy","enrollment":22},{"nctId":"NCT04186494","phase":"NA","title":"Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"St Vincent's University Hospital, Ireland","startDate":"2019-12-02","conditions":"Sleep Apnea, Obstructive","enrollment":30},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT04324229","phase":"NA","title":"Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Turku University Hospital","startDate":"2020-02-07","conditions":"Gestational Diabetes","enrollment":80},{"nctId":"NCT03151005","phase":"PHASE4","title":"The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2017-07-01","conditions":"Polycystic Ovary Syndrome (PCOS), Overweight, Obesity","enrollment":70},{"nctId":"NCT03862716","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2019-04-23","conditions":"Type 2 Diabetes Mellitus","enrollment":159},{"nctId":"NCT05952882","phase":"PHASE3","title":"Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility","status":"UNKNOWN","sponsor":"Mỹ Đức Hospital","startDate":"2023-11-01","conditions":"Polycystic Ovary Syndrome, Obesity, Infertility, Female","enrollment":188},{"nctId":"NCT03712098","phase":"PHASE2","title":"Daily Liraglutide for Nicotine Dependence","status":"COMPLETED","sponsor":"Rebecca Ashare","startDate":"2018-11-29","conditions":"Smoking Cessation, Weight, Body","enrollment":40},{"nctId":"NCT03757130","phase":"PHASE1","title":"Multiple Ascending Dose Study of AMG 598 in Adults With Obesity","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-11-26","conditions":"Obesity","enrollment":50},{"nctId":"NCT04781998","phase":"PHASE4","title":"Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?","status":"COMPLETED","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2021-07-01","conditions":"Mental Disorder, Metabolic Disturbance, Feasibility","enrollment":24},{"nctId":"NCT02960659","phase":"PHASE1, PHASE2","title":"Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-05-09","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT04605861","phase":"PHASE3","title":"The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-08-18","conditions":"Obese, Overweight","enrollment":414},{"nctId":"NCT03011021","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes","status":"UNKNOWN","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2017-01","conditions":"Type1 Diabetes Mellitus, Autoimmune Diabetes","enrollment":40},{"nctId":"NCT04657939","phase":"PHASE4","title":"Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2020-12-01","conditions":"Diabetes Mellitus, Type 2","enrollment":57},{"nctId":"NCT03948347","phase":"NA","title":"Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Jinan University","startDate":"2019-06-25","conditions":"Ischemic Stroke, Transient Ischemic Attack, Type 2 Diabetes Mellitus","enrollment":1708},{"nctId":"NCT05705388","phase":"NA","title":"POSE2.0 With GLP-1 Agonist for Obesity Management","status":"UNKNOWN","sponsor":"Emirates Health Services (EHS)","startDate":"2023-01-16","conditions":"Obesity","enrollment":50},{"nctId":"NCT03799198","phase":"PHASE4","title":"Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-07","conditions":"Obesity","enrollment":200},{"nctId":"NCT04903509","phase":"PHASE1","title":"A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-06-08","conditions":"Healthy","enrollment":95},{"nctId":"NCT02863419","phase":"PHASE3","title":"Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-08-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":711},{"nctId":"NCT02417103","phase":"PHASE3","title":"Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2011-12","conditions":"Obesity","enrollment":2},{"nctId":"NCT03955575","phase":"PHASE4","title":"Treatment of Bile Acid Malabsorption With Liraglutide","status":"COMPLETED","sponsor":"Filip Krag Knop","startDate":"2019-03-07","conditions":"Bile Acid Malabsorption","enrollment":52},{"nctId":"NCT02765399","phase":"PHASE4","title":"The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2015-02-01","conditions":"Type 2 Diabetes","enrollment":23},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT02973321","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-12-02","conditions":"Type 2 Diabetes Mellitus","enrollment":296},{"nctId":"NCT05294536","phase":"PHASE1","title":"A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2020-06-22","conditions":"Type 2 Diabetes","enrollment":50},{"nctId":"NCT05285397","phase":"NA","title":"Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.","status":"UNKNOWN","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","startDate":"2022-03-10","conditions":"Morbid Obesity","enrollment":60},{"nctId":"NCT04829903","phase":"NA","title":"Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin","status":"COMPLETED","sponsor":"Corporacion Parc Tauli","startDate":"2020-01-02","conditions":"Type 2 Diabetes Treated With Insulin, Obesity, Adolescent Obesity","enrollment":116},{"nctId":"NCT05268627","phase":"NA","title":"Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-01-27","conditions":"Obesity","enrollment":38},{"nctId":"NCT05225974","phase":"PHASE1","title":"A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2021-07-16","conditions":"Therapeutic Equivalency","enrollment":32},{"nctId":"NCT02898506","phase":"PHASE2","title":"Incretin-based Therapy in Late Preclinical Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2016-03","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT02611232","phase":"PHASE2","title":"Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults","status":"UNKNOWN","sponsor":"University of Oulu","startDate":"2015-12","conditions":"Type 1 Diabetes","enrollment":42},{"nctId":"NCT02908087","phase":"PHASE2","title":"Incretin-based Therapy in Early Diagnosed Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2016-03","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT03038620","phase":"PHASE4","title":"Impact of Liraglutide 3.0 on Body Fat Distribution","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-01","conditions":"Obesity, Visceral, Cardiovascular Diseases, Fat Disorder","enrollment":235},{"nctId":"NCT05029076","phase":"PHASE1","title":"Human Bioequivalence Test of Liraglutide Injection","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-05-21","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT04146155","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus","enrollment":200},{"nctId":"NCT02686177","phase":"PHASE4","title":"Effect of GLP-1 on Angiogenesis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05-18","conditions":"Type 2 Diabetes","enrollment":50},{"nctId":"NCT03480022","phase":"PHASE3","title":"Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS","status":"COMPLETED","sponsor":"Woman's","startDate":"2018-09-26","conditions":"Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android","enrollment":88},{"nctId":"NCT03347890","phase":"PHASE4","title":"Reward Mechanisms in Obesity","status":"COMPLETED","sponsor":"Zoltan Pataky","startDate":"2018-03-05","conditions":"Obesity","enrollment":70},{"nctId":"NCT04643301","phase":"NA","title":"Liraglutide for Low-responders After Bariatric Surgery","status":"WITHDRAWN","sponsor":"Zuyderland Medisch Centrum","startDate":"2020-12-21","conditions":"Obesity, Obesity, Morbid","enrollment":""},{"nctId":"NCT04839237","phase":"PHASE2","title":"The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients","status":"WITHDRAWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2017-12-01","conditions":"Obesity","enrollment":""},{"nctId":"NCT03671733","phase":"PHASE3","title":"Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2018-09-01","conditions":"Obesity","enrollment":150},{"nctId":"NCT03986008","phase":"PHASE3","title":"Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2019-12-01","conditions":"Obesity","enrollment":60},{"nctId":"NCT02616003","phase":"PHASE4","title":"Preoperative Condition in Giant Obese Patients","status":"COMPLETED","sponsor":"Sana Klinikum Offenbach","startDate":"2014-04","conditions":"Morbid Obesity, Bariatric Surgery Candidate","enrollment":50},{"nctId":"NCT03466021","phase":"PHASE4","title":"Effects of Liraglutide in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Claus Bogh Juhl","startDate":"2018-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":40},{"nctId":"NCT04057261","phase":"PHASE3","title":"Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease","status":"WITHDRAWN","sponsor":"RWTH Aachen University","startDate":"2020-11","conditions":"Type 2 Diabetes, Cardiovascular Diseases","enrollment":""},{"nctId":"NCT03010683","phase":"NA","title":"Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Athens","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus, Coronary Artery Disease","enrollment":60},{"nctId":"NCT03018028","phase":"PHASE3","title":"Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-01-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":243},{"nctId":"NCT03279731","phase":"PHASE3","title":"Binge Eating Liraglutide Intervention","status":"TERMINATED","sponsor":"Kelly Allison","startDate":"2017-09-29","conditions":"Binge-Eating Disorder","enrollment":36},{"nctId":"NCT03341429","phase":"PHASE4","title":"Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response","status":"COMPLETED","sponsor":"University College, London","startDate":"2018-08-22","conditions":"Obesity","enrollment":70},{"nctId":"NCT04122716","phase":"PHASE4","title":"Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet","status":"UNKNOWN","sponsor":"Signe Torekov","startDate":"2016-09","conditions":"Obesity","enrollment":215},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT04525300","phase":"PHASE3","title":"Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2020-05-24","conditions":"Obesity","enrollment":300},{"nctId":"NCT04487743","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2020-05-09","conditions":"Obesity","enrollment":300},{"nctId":"NCT02205528","phase":"PHASE2","title":"A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-18","conditions":"Diabetes, Diabetes Mellitus Type 2","enrollment":108},{"nctId":"NCT04373967","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-04-29","conditions":"Type 2 Diabetes","enrollment":424},{"nctId":"NCT02082496","phase":"PHASE2","title":"GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2014-06","conditions":"Obesity","enrollment":50},{"nctId":"NCT03011008","phase":"PHASE4","title":"Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus","status":"UNKNOWN","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2017-01","conditions":"Type 1 Diabetes Mellitus, Autoimmune Diabetes","enrollment":20},{"nctId":"NCT02351232","phase":"PHASE2, PHASE3","title":"The Lira Pump Trial","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2015-02","conditions":"Type 1 Diabetes","enrollment":44},{"nctId":"NCT02043054","phase":"PHASE3","title":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":90},{"nctId":"NCT01753362","phase":"PHASE3","title":"Liraglutide In Overweight Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2012-12","conditions":"Type 1 Diabetes","enrollment":84},{"nctId":"NCT04137328","phase":"NA","title":"Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-11-30","conditions":"Diabetic Neuropathic Pain","enrollment":60},{"nctId":"NCT01966978","phase":"PHASE4","title":"The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-11","conditions":"Diabetes Mellitus, Type 2, Diabetes","enrollment":157},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT02198209","phase":"PHASE4","title":"Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-12","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT02488057","phase":"PHASE4","title":"Improving Beta Cell Function in Mexican American Women With Prediabetes","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2016-05","conditions":"Pre-Diabetes","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Victoza","victoza","Nuo he li","Placebo"],"phase":"marketed","status":"active","brandName":"Liraglutide injection","genericName":"Liraglutide injection","companyName":"Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca","companyId":"unidad-de-cirugia-bariatrica-hospital-civil-dr-juan-i-menchaca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liraglutide is a glucagon-like peptide 1 receptor agonist used to treat various conditions, including Type 1 Diabetes Mellitus, Autoimmune Diabetes, Obesity, Type 2 Diabetes Treated With Insulin, and Adolescent Obesity. It works by activating the glucagon-like peptide 1 receptor, a protein involved in glucose regulation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}